In a potential breakthrough in cancer research, scientists at the University of Pennsylvania have genetically engineered patients' T cells — a type of white blood cell — to attack cancer cells in advanced cases of a common type of leukemia .
Two of the three patients who received doses of the designer T cells in a clinical trial have remained cancer-free for more than a year, the researchers said.
Experts not connected with the trial said the feat was important because it suggested that T cells could be tweaked to kill a range of cancers, including ones of the blood, breast and colon.
Future advances like this have been put at risk, of course, by the federal government's ongoing nationalization of healthcare.
No comments:
Post a Comment